Thus, the COMBI-AD trial (NCT 01682083) evaluated 12 months of treatment based on adjuvant therapy with dabrafenib plus trametinib or with placebo in patients with resected stage III melanoma with BRAF V600 mutations [55]. This evidence concerns the gene BRAF and melanoma.